Analysts at Leerink Swann initiated coverage on shares of Five Prime Therapeutics (NASDAQ:FPRX) in a report released on Thursday. The brokerage set an “outperform” rating and a $24.00 price target on the biotechnology company’s stock. Leerink Swann’s price objective would indicate a potential upside of 68.07% from the stock’s current price.

FPRX has been the topic of several other reports. BidaskClub cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Wedbush assumed coverage on Five Prime Therapeutics in a research report on Thursday, May 17th. They set a “neutral” rating and a $17.00 price objective on the stock. Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 17th. ValuEngine cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 28th. Finally, JPMorgan Chase & Co. assumed coverage on Five Prime Therapeutics in a research report on Friday, June 15th. They set a “neutral” rating and a $19.00 price objective on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $31.70.

Shares of NASDAQ FPRX traded down $0.10 during trading on Thursday, reaching $14.28. The company had a trading volume of 2,914 shares, compared to its average volume of 378,891. Five Prime Therapeutics has a 12-month low of $12.52 and a 12-month high of $48.87. The stock has a market cap of $483.52 million, a P/E ratio of -2.71 and a beta of 3.24.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.30. Five Prime Therapeutics had a negative return on equity of 40.61% and a negative net margin of 206.02%. The company had revenue of $7.58 million for the quarter, compared to analysts’ expectations of $5.87 million. equities research analysts expect that Five Prime Therapeutics will post -4.02 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC lifted its holdings in Five Prime Therapeutics by 35.7% in the first quarter. Millennium Management LLC now owns 357,747 shares of the biotechnology company’s stock valued at $6,146,000 after acquiring an additional 94,035 shares during the period. Citadel Advisors LLC lifted its holdings in Five Prime Therapeutics by 61.1% in the second quarter. Citadel Advisors LLC now owns 147,047 shares of the biotechnology company’s stock valued at $2,325,000 after acquiring an additional 55,783 shares during the period. ARK Investment Management LLC lifted its holdings in Five Prime Therapeutics by 165.9% in the second quarter. ARK Investment Management LLC now owns 183,094 shares of the biotechnology company’s stock valued at $2,895,000 after acquiring an additional 114,240 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Five Prime Therapeutics by 6.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,041,750 shares of the biotechnology company’s stock valued at $17,897,000 after acquiring an additional 67,474 shares during the period. Finally, Algert Global LLC bought a new position in shares of Five Prime Therapeutics in the second quarter worth about $476,000. 86.31% of the stock is currently owned by institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Article: Price to Earnings Ratio (PE)

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.